Photo by freestocks from unsplash
The publication in 2017 of the KEYNOTE 045 prospective randomized phase 3 trial comparing pembrolizumab anti PD1 antibody with conventional cytotoxic chemotherapy in treatment of recurrent urothelial cancer (1) marked… Click to show full abstract
The publication in 2017 of the KEYNOTE 045 prospective randomized phase 3 trial comparing pembrolizumab anti PD1 antibody with conventional cytotoxic chemotherapy in treatment of recurrent urothelial cancer (1) marked a watershed for immune treatment to displace conventional cytotoxic medications.
Keywords:
keynote 045;
urothelial cancer;
commentary year;
year follow;
follow pembrolizumab
Journal Title: Translational andrology and urology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Translational andrology and urology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!